Mark Coleman - 26 Feb 2026 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Nick Pizzie, Attorney-in-Fact
Issuer symbol
AXSM
Transactions as of
26 Feb 2026
Net transactions value
-$4,027,750
Form type
4
Filing time
27 Feb 2026, 19:00:07 UTC
Previous filing
25 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coleman Mark Director C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Nick Pizzie, Attorney-in-Fact 27 Feb 2026 0001658379

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Sale $4,027,750 -25,000 -35% $161.11 47,140 26 Feb 2026 Direct F1, F2, F3
holding AXSM Common Stock 403,856 26 Feb 2026 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the sale of underlying shares of previously exercised stock options.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.33 and $162.26.
F4 Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.